Liquid biopsy PD-L1 test, 8/16
August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy.